MacroGenics, Inc.
Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies

Abstract:

The present invention is directed to a dosing regimen for administering a CD 123.times.CDS bispecific diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The present invention is also directed to a dosing regimen for administering a CD 123.times.CDS bispecific diabody in combination with a molecule capable of binding PD-1 or a natural ligand of PD-1 (a "PD-1 or PD-1 ligand binding molecule") to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such regimens for administering the sequence-optimized CD 123.times.CDS bispecific diabody, "DART-A," which is capable of simultaneous binding to CD 123 and CDS.